 IN recent months, companies linked to the local Covid-19 vaccine supply chain have drawn keen interest from the market, especially those identified as able to undertake the fill and finish process of the vaccine. In particular, Bursa-listed Duopharma Biotech Bhd and Pharmaniaga Bhd have come under the spotlight. But Apex Healthcare Bhd chairman and CEO Dr Kee Kirk Chin highlights another crucial aspect that has yet to receive much attention vaccine distribution. 